Latest from Mayo Clinic Cancer Center

Shaji Kumar, MD, discusses the addition of the BCL-2 inhibitor venetoclax to the combination of bortezomib and dexamethasone significantly improved progression-free survival, overall response rate, very good partial response, and minimal residual disease negativity rates in the phase III BELLINI trial in relapsed/refractory patients with multiple myeloma.
Manoj K. Jain, MD, discusses the use of radioligand therapy in prostate cancer.
Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses research being done with antibody-drug conjugates (ADCs) in advanced bladder cancer.
Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses molecular signatures in metastatic renal cell carcinoma (mRCC).
Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses reasons to explore biosimilars in oncology.
Manoj K. Jain, MD, discusses new imaging modalities and what they could mean for the field going forward.
Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses treatment beyond progression on CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.
Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in metastatic renal cell carcinoma (mRCC).
Publication Bottom Border
Border Publication
x